Dedicated distributor force built for the orthopedic, sports, regenerative medicine, and pain management and rehabilitation (PMR) channels, supporting commercialization of Vector's peptide portfolio.
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results